D
Donald E. Low
Researcher at University of Toronto
Publications - 362
Citations - 25624
Donald E. Low is an academic researcher from University of Toronto. The author has contributed to research in topics: Population & Streptococcus pneumoniae. The author has an hindex of 88, co-authored 359 publications receiving 24384 citations. Previous affiliations of Donald E. Low include Trillium Health Centre & New York City Department of Health and Mental Hygiene.
Papers
More filters
Journal ArticleDOI
Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.
Vanessa Allen,Leo Mitterni,Christine Seah,Anuradha Rebbapragada,Irene Martin,Colin Lee,Heather Siebert,Lynn Towns,Roberto G. Melano,Donald E. Low +9 more
TL;DR: The rate of clinical failure following treatment of N. gonorrhoeae infections with cefixime was relatively high at a Toronto clinic and was associated with elevated MICs.
Journal ArticleDOI
Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing
Dea Shahinas,Michael S. Silverman,Taylor Sittler,Charles Y. Chiu,Peter T. Kim,Emma Allen-Vercoe,Scott Weese,Andrew Wong,Donald E. Low,Donald E. Low,Dylan R. Pillai +10 more
TL;DR: The microbial diversity of pre- and posttransplant stool specimens from CDI patients is explored using deep sequencing of the 16S rRNA gene to explore the human microbial diversity in patients with Clostridium difficile infection (CDI) disease after FT.
Journal Article
Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Anna Norrby-Teglund,Rupert Kaul,Donald E. Low,Allison McGeer,Duane W. Newton,Jan Andersson,Ulf Andersson,Malak Kotb +7 more
TL;DR: In all IVIG-treated patients, the capacity to neutralize the superantigenic activity, produced by their respective GAS isolate or by purified streptococcal pyrogenic exotoxins, increased in plasma following IVIG administration, and suggests that IVIG may be useful in the treatment of severe invasive strePTococcal infections.
Journal ArticleDOI
FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Thomas M. File,Donald E. Low,Paul B. Eckburg,George H. Talbot,H. David Friedland,Jon Lee,Lily Llorens,Ian A. Critchley,Dirk Thye,John Pullman,Philip Giordano,James Welker,Paul Manos,Purvi Mehra,Thomas M. File,Joseph De Santo,Bhaskar Venkateswaralu,Christian Schrock,William Tillis,Jan Alan Winetz,J. Mario Gonzalez,Anthony Ramage,Dwight D. Eisenhower,Coenie Koegelenberg,Ingrid Engelbrecht,Jaco Jurgens,Ishmail Mitha,Johannes Breedt,Mashra Gani,Johannes Roos,Matthys Basson,Louis Van Zyl,Ronel Meeding,Muhammed Fulat,Marius Le Roux,Pablo Bonvehí,Maria Cristina Ganaha,Ana Leticia Gurini,Gustavo Lopardo,Lucia Cristina,Sergio Edwardo Prieto,Claudia Gabriela Rodiguez,Ricardo Augusto Teijeiro,Elida Carmen Pallone,Daniel Horacio Pryluka,Clovis Arns da Cunha,Nilton Brandao da Silva,Antonio Tarcisio de Faria Freire,Carlos Ernesto Ferreira Starling,Jussara Costa Fiterman,Fernando Gongora Rubio,Luis Carlos Losso,Maria Patelli,Juliani Souza Lima,Paulo José Zimermann Teixeira,Maria Auxiliadora Carmo Moreira,Júlio César Abreu de Oliveira,Vsevolod Roudas,Evgeny A. Gamal,Igor Leschenko,Vladimir A. Rudnov,Anna G. Yevdokimova,Arkadiy L. Vertkin,Yuriy M. Ambalov,Irina V. Dvoryashina,Elmira Zilber,Rustem F. Khamitov,Anna N. Galustyan,Olga V. Reshetko,Victoria Arama Senior,Mihaela Flavia Grosan,Gabriela Jimborean,Mihaela Lupse,Gheorgita Aron,Dan Olteanu,Maria Puschita,Claudia Gavris,Voicu Mircea Tudorache,Vania Youroukova,Mila Petkova,Evelina Troshanova,Mari Dzhabalyan,George Kavtaradze,Manana Makhviladze,Revaz Tabukashvili,Marco Pons,Jorge Garbino,Daniel Genne,Madeleine Rothen,Juan Oriz de Saracho,Alberto Capelastegui,Rosario Menéndez,Antoni Torres,Conrado Shum,V Falcó,Emilio Bouza,Jean-Pierre Bru,Benoit Misset,Bruno Mégarbane,Jean Pierre Sollet,Jean-Michel Molina,Klaus Dalhoff,Joachim Lorenz,Wolfgang Petermann,Gernot Rohde,Christian Schumann,Selcuk Tasci,Joachim Zerbst,Wolfgang Auch-Schwelk,Norbert Suttorp,Rolf Henrich,Andreas Fertl,Christian Grohe,Christian Jakobeit,Karl-Matthius Deppermann,Halina Batura-Gabryel,Danuta Pupek-Musialik,Pawe Piotrowicz,Czeslaw Marcisz,Krzysztof Czarnobilski,Renata Jankowska,Krzysztof Janik,Malgorzata Gutowska-Jablonska,Maciej Hamankiewicz,Jan Kus,Andrzej Rydzewski,Jan Dulawa,Ewa Ziolko,Eliza Baranska,Marian Wendland,Ewa Trebas-Pietras,Ireneusz Tyszkiewic,Johannes Bonelli,Zoltán Balikó,Márta Bisits,Gyorgy Losonczy,Zsuzsa Mark,Istvan Albert,Eva Francovszky,Karoly Fonay,Tetiana Tetiana Pertseva,Volodymyr Yefimov,Volodymyr Havrysyuk,Vasyl Melnyk,Lyudmyla Yashyna,Nadiya Monogarova,Yuriy Kolchyn,Roman Dutka,Oleksandr Smolyanyi,Nadiya Tryshchuk,Igor Kaydashev,Victoria Rodionova,Vasyl Neyko,Ivan Chopey,Birute Alekniene,Ginataras Kramilius,Stanislovas Naudziunas,Skaidrius Miliauskas,Vitalija Nausediene,Arvydas Valavicius,Marija Mitic-Milikic,Dusica Celeketic,Zorica Lazic,Nikola Milinic,Tatjana Pejcic,Kai Sukles,Martti Jaanus,Sulev Meriste,Datin Hjh Aziah Ahmad Mahayiddin,Abdul Pazak Bin Abdul Muttalif,Kiew Kuang Kiat,Roslina Binte,Abdul Manap,Noor Aliza bt Md Tarekh,Thanomsak Anekthananon,Piroon Mootsikapun,Poj Intalapaporn,Chaicharn Pothirat,Pinyo Horsin,Charoen Churchottaworn,Anan Wattanathum,Andrej Dukat,Jan Plutinsky +182 more
TL;DR: Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV and was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class.
Journal ArticleDOI
A Review of Streptococcus pneumoniae Infection Treatment Failures Associated with Fluoroquinolone Resistance
Jeffrey D. Fuller,Donald E. Low +1 more
TL;DR: Physicians should be aware, when treating pneumococcal respiratory tract infections in older patients with a fluoroquinolone, that clinical failures might occur, especially for patients with comorbid illnesses and a history of recent fluoroquolone use.